Table 1.
Patient No. | Agea and Gender | Cancer History (Age at Diagnosis) | BRCA1b | Other Health Issues |
---|---|---|---|---|
II.1 | 80 M | none | WT | none |
II.2 | 87 M | pancreatic cancer (85), colon cancer (70) | WT | none |
II.3 | 65 F | ovarian cancer (64) | WT | none |
II.4 | 60 M | adrenal cancer (50) | WT | none |
II.5 | 83 M | pheochromocytoma (50), lung adenocarcinoma (55), melanoma (78), bronchoalveolar lung (80) | WT | none |
II.6 | 90 F | endometrial cancer (50), breast cancer (73) | mutant | monoclonal gammopathy of undetermined significance |
III.1 | 50 M | none | WT | dysplastic nevi, chondroma (elbow), colon polyps |
III.3 | 52 M | testicular cancer (28), prostate cancer (55) | mutant | none |
III.4 | 45 F | none | WT | none |
III.7 | 48 F | melanoma (38) | mutant | dysplastic nevi, endometrial atypia, focal nodular hyperplasia (liver), prophylactic surgeriesc |
IV.1 | 19 F | none | WT | none |
IV.3 | 22 F | none | mutant | none |
Age at the time of sample acquisition or at the time of death.
WT, wild-type for both BRCA1 alleles; mutant, BRCA1 5382insC heterozygous.
Bilateral mastectomies, hysterectomy, and oophorectomies.